These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22218453)

  • 1. Biosimilars.
    Malozowski S
    Arq Bras Endocrinol Metabol; 2011 Nov; 55(8):669. PubMed ID: 22218453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: State of Clinical and Regulatory Science.
    Klein AV; Wang J; Feagan BG; Omoto M
    J Pharm Pharm Sci; 2017; 20(1):332-348. PubMed ID: 29145936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: are they bioequivalent?
    Gomollón F
    Dig Dis; 2014; 32 Suppl 1():82-7. PubMed ID: 25531357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key considerations in the preclinical development of biosimilars.
    Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
    Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competition in the Age of Biosimilars.
    Chandra A; Vanderpuye-Orgle J
    JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
    Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
    Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars: what the oncologist should know.
    Thill M; Thatcher N; Hanes V; Lyman GH
    Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars and follow-on biologics.
    Fuhr JP
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):149-50. PubMed ID: 19402802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights of biosimilars through SWOT analysis.
    Patel MM; Shah PJ; Patel BM
    Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.